Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. However, there is little known about targeted therapeutics for the treatment of this devastating tumor. Among the growth factor signaling cascades deregulated in HCC, evidences suggest that the WNT/Frizzled – mediated signaling pathway plays a key role in the hepatic carcinogenesis. Aberrant activation of the signaling in HCC is mostly due to deregulated expression of the Wnt/β-catenin signaling components. This leads to the activation of the β-catenin/TCF dependent target genes, which controls cell proliferation, cell cycle, apoptosis or motility. It has been shown that disruption of the Wnt/β-catenin signaling cascade displayed anti-cancer properties in HCC. Currently, no therapeutic molecules targeting the WNT pathway are available or under clinical evaluation for the treatment of HCC. This review will discuss the identified potential molecular targets related to the canonical WNT signaling pathway and their potential therapeutic usefulness.
Keywords: β-catenin, frizzled, hepatocellular carcinoma, molecular target, targeted therapy, WNT, (WNT/FZD)-mediated signaling, The Canonical/-catenin Pathway, TCF/LEF, FZD7 receptor, catenin signaling, hepatitis/cirrhosis, iRNA-mediated, TCF-4 isoforms
Anti-Cancer Agents in Medicinal Chemistry
Title: Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Volume: 11 Issue: 6
Author(s): Sarah B. Nambotin, Jack R. Wands and Miran Kim
Affiliation:
Keywords: β-catenin, frizzled, hepatocellular carcinoma, molecular target, targeted therapy, WNT, (WNT/FZD)-mediated signaling, The Canonical/-catenin Pathway, TCF/LEF, FZD7 receptor, catenin signaling, hepatitis/cirrhosis, iRNA-mediated, TCF-4 isoforms
Abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. However, there is little known about targeted therapeutics for the treatment of this devastating tumor. Among the growth factor signaling cascades deregulated in HCC, evidences suggest that the WNT/Frizzled – mediated signaling pathway plays a key role in the hepatic carcinogenesis. Aberrant activation of the signaling in HCC is mostly due to deregulated expression of the Wnt/β-catenin signaling components. This leads to the activation of the β-catenin/TCF dependent target genes, which controls cell proliferation, cell cycle, apoptosis or motility. It has been shown that disruption of the Wnt/β-catenin signaling cascade displayed anti-cancer properties in HCC. Currently, no therapeutic molecules targeting the WNT pathway are available or under clinical evaluation for the treatment of HCC. This review will discuss the identified potential molecular targets related to the canonical WNT signaling pathway and their potential therapeutic usefulness.
Export Options
About this article
Cite this article as:
B. Nambotin Sarah, R. Wands Jack and Kim Miran, Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/187152011796011019
DOI https://dx.doi.org/10.2174/187152011796011019 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets The Fight against Human Viruses: How NMR Can Help?
Current Medicinal Chemistry Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Combined Treatment with Laser Ablation and Tyrosine-Kinase Inhibitor as A Novel Multimodality Approach to Locally Advanced Thyroid Cancer: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications
Current Drug Targets Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro
Anti-Cancer Agents in Medicinal Chemistry Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?
Anti-Cancer Agents in Medicinal Chemistry Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Screening of Hub Gene Targets for Lung Cancer via Microarray Data
Combinatorial Chemistry & High Throughput Screening Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase
Medicinal Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy A Review on Electrochemical Sensing of Cancer Biomarkers Based on Nanomaterial - Modified Systems
Current Analytical Chemistry Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design